March 2, 2007

Intervet reports growth in global operations

Dutch-based Intervet, a company manufacturing animal pharmaceuticals, feed additives and vaccines, reported a 3 percent growth in profits to EUR 1.125 billion on top of strong autonomous growth across all regions and product lines.

Outpacing market growth, EBIT before incidentals increased 2 percent to EUR 213 million, resulting in an EBIT margin of 18.9 percent. Divestments and acquisitions had a negative impact on revenues of 3 percent.

Autonomous growth in Europe, at 5 percent, was slower than that in North America, where revenues from ongoing operations grew 12 percent.

Intervet received important product approvals for Zilmax, a feed additive for cattle and PreveNile, a West Nile Virus vaccine for horses last year.